Estradiol: patches, gels, vaginal and oral products

Transdermal patches deliver estrogen through skin. Product labels differ in indications and replacement schedules. Adhesion and skin irritation can affect practical use. FDA has recently addressed patch availability; a pharmacist can help identify appropriate substitutions rather than assuming every patch is in stock. ^{1, 5}

These are skin-applied systemic products. They have product-specific application and transfer precautions. A skin gel or spray should not be mistaken for a vaginal formulation. Contact with other people and the use of other skin products belong in the pharmacist discussion. ²

Vaginal products may be selected for dryness and related local symptoms. The exact product matters because vaginal route alone does not establish its level of systemic exposure. Ask whether the intended product addresses local symptoms or also has a systemic role. ³

Oral estrogen is another systemic route. Abnormal bleeding, breast or other hormone-sensitive cancer, clot history, liver disease and other medicines require review. For systemic estrogen in a person with a uterus, ask how the endometrium will be protected. Do not infer current boxed-warning wording from an older hormone label. ^{2, 4}

A vaginal product used for genitourinary symptoms and a systemic patch, gel, spray or tablet are not interchangeable versions of one plan. The route changes exposure, labeled uses, precautions and whether endometrial protection may be considered for a person with a uterus. Ask whether the goal is local symptom relief or systemic menopause treatment. A compounded cream containing estradiol, estriol, testosterone or progesterone is a separate mixture and cannot borrow the approval of its individual ingredients. ^{1, 2, 3, 4}

Before systemic therapy, discuss unexplained vaginal bleeding, breast or uterine cancer history, blood clots, stroke, heart disease, liver disease, migraine and smoking. New vaginal bleeding after menopause needs evaluation rather than automatic hormone adjustment. Seek urgent care for chest pain, sudden breathlessness, one-sided weakness, a severe new headache, vision change or painful leg swelling. Breast changes should be assessed through the planned screening and diagnostic pathway. Risk depends on route, dose, duration and individual history. ^{1, 2, 4}

Follow-up should ask whether the specific symptom target improved and whether side effects, bleeding or medical history changed. Skin products need application-site and transfer instructions; patches need placement and adhesion review. Vaginal products require their own application plan. If a uterus is present, ask how the clinician is addressing endometrial safety for the selected systemic regimen. Do not add over-the-counter hormones or a second estrogen product without checking for duplicated exposure. ^{1, 2, 3, 4}